亚太地区呼吸吸入器市场预测至 2028 年 – COVID-19 影响和区域分析 – 按产品类型 [雾化器、计量吸入器 (MDI) 和干粉吸入器]、技术(手动操作吸入器和数字操作吸入器)和疾病适应症(哮喘、慢性阻塞性肺病、肺动脉高压等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 170    |    Report Code: BMIRE00028388    |    Category: Life Sciences

Asia Pacific Respiratory Inhalers Market

亚太呼吸吸入器市场预计将从2022年的63.9709亿美元增长到2028年的92.9748亿美元。预计2022年至2028年的复合年增长率为6.4%。

增加产品开发活动,推动亚太地区呼吸吸入器市场增长

凭借新的医学知识和有效的药物,各种哮喘吸入器的治疗不断取得进展。呼吸机联合疗法的使用不断增加,以及主要参与者在开发复杂呼吸机吸入器方面的投资不断增加,正在推动对呼吸吸入器的需求。除了该设备具有便携性、便利性和有效性等众多优势外,越来越多的产品批准和开发预计将在未来几年加强对呼吸吸入器的需求。近年来发生了一些重大进展和批准。例如,2022 年 11 月,阿斯利康与 Avillion 合作开发了哮喘救援吸入器 PT027。 PT027 是一种加压计量吸入器,可输送固定剂量的两种组合哮喘药物:沙丁胺醇(一种短效 β2 激动剂)和布地奈德(一种抗炎吸入皮质类固醇)。同样,2020年12月,欧姆龙推出了全球首款帮助哮喘儿童的喘息检测设备WheezeScan,这是小儿哮喘管理领域的重大突破。 WheezeScan 帮助幼儿的父母检测喘息——这是即将到来的哮喘发作的明确指标——并采取相应行动。因此,各种市场参与者的不断进步和产品批准可能会在预测期内促进亚太呼吸吸入器市场的增长。

亚太呼吸吸入器市场吸入器市场概览

亚太地区市场包括日本、中国、印度、韩国、澳大利亚和亚太地区其他地区。亚太地区预计将成为增长最快的地区,其中中国占据主要市场份额。中国是亚太地区发展最快的经济体之一,GDP达18万亿美元,占全球经济的18%。该国的医疗保健支出占GDP的7.1%。 《中国宏观经济杂志2021》显示,60岁及以上人口约2.64亿,占全国总人口的18.7%。大量老年人口的存在增加了呼吸系统疾病的负担,因为老年人口容易出现各种健康状况。根据前沿媒体 2022 年 6 月发布的公共卫生报告,中国最新的慢性阻塞性肺病全国调查显示,中国的慢性阻塞性肺病病例几乎占全球所有慢性阻塞性肺病病例的 25%。与10年前的调查结果相比,40岁以上人群的COPD患病率增加了67%,已达到流行病的程度。此外,哮喘是该国的一项重大公共卫生挑战,影响着数百万人。根据国家医学图书馆的数据,2019 年哮喘患病率为 4.2%,相当于该国 4570 万人。这进一步增加了对呼吸吸入器的需求。此外,COVID-19 的爆发创造了对呼吸吸入器的需求。其他国家各公司的地域扩张也可能支持市场增长。

亚太呼吸吸入器市场收入和预测至 2028 年(百万美元)

亚太呼吸吸入器市场细分< /strong>

亚太呼吸吸入器市场根据产品类型、技术、疾病适应症和国家/地区进行细分。

<根据产品类型,亚太地区呼吸吸入器市场分为雾化器、计量吸入器 (MDI) 和干粉吸入器。 2022 年,干粉吸入器细分市场在亚太呼吸吸入器市场中占据最大份额。

根据技术,亚太呼吸吸入器市场分为手动操作吸入器和手动操作吸入器。数字操作的吸入器。 2022 年,手动操作吸入器细分市场在亚太呼吸吸入器市场中占据较大份额。

根据疾病适应症,亚太呼吸吸入器市场细分为哮喘、慢性阻塞性肺病、肺动脉高压等。 2022 年,哮喘细分市场在亚太呼吸吸入器市场中占据最大份额。

根据国家/地区,亚太呼吸吸入器市场已分为中国、印度、日本、韩国、澳大利亚和亚太其他地区。 2022 年,中国在亚太呼吸吸入器市场占据主导地位。

阿斯利康 (AstraZeneca Plc); Beximco 制药有限公司;勃林格殷格翰国际有限公司;西普拉有限公司;葛兰素史克公司;皇家飞利浦公司;欧姆龙公司; OPKO 健康公司; PARI 呼吸设备有限公司;和 Teva Pharmaceutical Industries Ltd 是亚太呼吸吸入器市场的领先公司。



Asia Pacific Respiratory Inhalers Strategic Insights

Strategic insights for Asia Pacific Respiratory Inhalers involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-respiratory-inhalers-market-strategic-framework.webp
Get more information on this report

Asia Pacific Respiratory Inhalers Report Scope

Report Attribute Details
Market size in 2022 US$ 6,397.09 Million
Market Size by 2028 US$ 9,297.48 Million
Global CAGR (2022 - 2028) 6.4%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 产品类型
  • 雾化器
  • 定量吸入器
  • 干粉吸入器
By 技术
  • 手动吸入器和数字吸入器
By 疾病适应症
  • 哮喘
  • 慢性阻塞性肺病
  • 肺动脉高压
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • AstraZeneca Plc
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd
  • GSK Plc
  • Koninklijke Philips NV
  • OMRON Corp
  • OPKO Health, Inc
  • PARI Respiratory Equipment, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Get more information on this report

    Asia Pacific Respiratory Inhalers Regional Insights

    The regional scope of Asia Pacific Respiratory Inhalers refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-respiratory-inhalers-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Respiratory Inhalers Market

    1. AstraZeneca Plc
    2. Beximco Pharmaceuticals Ltd.
    3. Boehringer Ingelheim International GmbH
    4. Cipla Ltd
    5. GSK Plc 
    6. Koninklijke Philips NV
    7. OMRON Corp   
    8. OPKO Health, Inc
    9. PARI Respiratory Equipment, Inc.
    10. Teva Pharmaceutical Industries Ltd
    Frequently Asked Questions
    How big is the Asia Pacific Respiratory Inhalers Market?

    The Asia Pacific Respiratory Inhalers Market is valued at US$ 6,397.09 Million in 2022, it is projected to reach US$ 9,297.48 Million by 2028.

    What is the CAGR for Asia Pacific Respiratory Inhalers Market by (2022 - 2028)?

    As per our report Asia Pacific Respiratory Inhalers Market, the market size is valued at US$ 6,397.09 Million in 2022, projecting it to reach US$ 9,297.48 Million by 2028. This translates to a CAGR of approximately 6.4% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Respiratory Inhalers Market report typically cover these key segments-

  • 产品类型 (雾化器, 定量吸入器, 干粉吸入器)
  • 技术 (手动吸入器和数字吸入器)
  • 疾病适应症 (哮喘, 慢性阻塞性肺病, 肺动脉高压)
  • What is the historic period, base year, and forecast period taken for Asia Pacific Respiratory Inhalers Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Respiratory Inhalers Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Asia Pacific Respiratory Inhalers Market?

    The Asia Pacific Respiratory Inhalers Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca Plc
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd
  • GSK Plc
  • Koninklijke Philips NV
  • OMRON Corp
  • OPKO Health, Inc
  • PARI Respiratory Equipment, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Who should buy this report?

    The Asia Pacific Respiratory Inhalers Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Respiratory Inhalers Market value chain can benefit from the information contained in a comprehensive market report.